No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
-aminosalicylic acid |
Aminosalicylic acid |
D00162 |
- |
- |
2件: 96, 97 |
2 |
0.25 mg rpc1063 |
- |
- |
- |
- |
2件: 96, 97 |
3 |
0114-0006b |
- |
- |
- |
- |
2件: 46, 96 |
4 |
10% metronidazole ointment |
Metronidazole |
D00409, D05016, D05017 |
- |
- |
1件: 96 |
5 |
1000 iu d3 |
- |
- |
- |
- |
1件: 96 |
6 |
13-valent pneumococcal conjugated vaccine (pcv13) |
- |
- |
- |
- |
1件: 96 |
7 |
1mg rpc1063 |
- |
- |
- |
- |
1件: 96 |
8 |
2'-fucosyllactose |
- |
- |
- |
- |
2件: 96, 97 |
9 |
23-valent polysaccharide pneumococcal vaccine |
- |
- |
- |
- |
1件: 96 |
10 |
23-valent polysaccharide pneumococcal vaccine (pneumovax tm) |
- |
- |
- |
- |
2件: 96, 97 |
11 |
4-aminosalicylic acid |
Aminosalicylic acid |
D00162 |
- |
- |
1件: 96 |
12 |
4-aminosalicylic acid extended release granules |
Aminosalicylic acid |
D00162 |
- |
- |
1件: 96 |
13 |
40 mg msb11022 |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
14 |
42942019 |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
15 |
5-aminosalicylate |
Mesalazine |
D00377 |
- |
- |
2件: 96, 97 |
16 |
5-aminosalicylate (pentasa, ferring) |
Mesalazine |
D00377 |
- |
- |
2件: 96, 97 |
17 |
5-aminosalicylic acid |
Aminosalicylic acid |
D00162 |
- |
- |
2件: 96, 97 |
18 |
5-asa |
Mesalazine |
D00377 |
- |
- |
2件: 96, 97 |
19 |
5-asa, prednisone, azathioprine or remicade |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 96 |
20 |
5-htp |
- |
- |
- |
- |
2件: 96, 97 |
21 |
5000 iu d3 |
- |
- |
- |
- |
1件: 96 |
22 |
549-0261/f02-01 |
- |
- |
- |
- |
2件: 96, 97 |
23 |
6 mercaptopurine |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 96, 97 |
24 |
6-[(methyl-4-nitro-1h-imidazol-5-yl)thio]-1h-purine |
- |
- |
- |
- |
1件: 96 |
25 |
6-mp |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 96, 97 |
26 |
683699 |
- |
- |
- |
- |
1件: 96 |
27 |
6mp |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 94, 96 |
28 |
80 mg dr-6mp |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
1件: 96 |
29 |
99mtc-s-hynic certolizumab pegol |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 46, 96 |
30 |
?-3 polyunsaturated fatty acid |
- |
- |
- |
- |
1件: 96 |
31 |
[14c]-rpc1063 solution (0.1 mg/ml) for oral administration |
- |
- |
- |
- |
3件: 13, 96, 97 |
32 |
[18f]fspg |
- |
- |
- |
- |
2件: 96, 97 |
33 |
Ab1010 |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
34 |
Abatacept |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
24件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
35 |
Abbv-066 |
- |
- |
- |
- |
2件: 96, 97 |
36 |
Abr-215062 sodium salt |
- |
- |
- |
- |
2件: 13, 96 |
37 |
Abt-494 |
- |
- |
- |
- |
3件: 46, 96, 97 |
38 |
Abt-874 |
- |
- |
- |
- |
1件: 96 |
39 |
Abx464 |
Abx464 |
- |
- |
- |
3件: 46, 96, 97 |
40 |
Accelerated 1 hour-infusion |
- |
- |
- |
- |
2件: 96, 97 |
41 |
Accelerated 30 minutes-infusion |
- |
- |
- |
- |
2件: 96, 97 |
42 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
43 |
Adalimumab |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
44 |
Adalimumab (40 mg) |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
45 |
Adalimumab (d2e7) |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 271 |
46 |
Adalimumab 40 mg eow or ew |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
47 |
Adalimumab and infliximab |
Adalimumab, Infliximab |
D02597, D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
48 |
Adalimumab injection |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
49 |
Adalimumab prn |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
50 |
Adult human mesenchymal stem cells |
Remestemcel-l |
D09719 |
- |
- |
2件: 85, 96 |
51 |
Agri-king synbiotic (aksb) |
- |
- |
- |
- |
1件: 96 |
52 |
Ain457 |
- |
- |
- |
- |
7件: 13, 37, 41, 46, 56, 96, 271 |
53 |
Albendazole |
Albendazole |
D00134 |
- |
- |
1件: 96 |
54 |
Albendazole (eskazole) |
Albendazole |
D00134 |
- |
- |
1件: 96 |
55 |
Alemtuzumab |
Alemtuzumab |
D02802 |
- |
- |
13件: 13, 15, 19, 20, 46, 51, 60, 63, 65, 85, 96, 164, 284 |
56 |
Alequel |
- |
- |
- |
- |
1件: 96 |
57 |
Alfacalcidol |
Alfacalcidol |
D01518 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
6件: 41, 46, 49, 50, 96, 235 |
58 |
Alicaforsen |
Alicaforsen |
- |
- |
- |
2件: 96, 97 |
59 |
Alicalm (polymeric liquid formula) |
- |
- |
- |
- |
1件: 96 |
60 |
Allo-asc |
- |
- |
- |
- |
1件: 96 |
61 |
Allo-asc-cd |
- |
- |
- |
- |
1件: 96 |
62 |
Allogeneic bone marrow derived human mesenchymal stem cells (hmscs) |
- |
- |
- |
- |
1件: 96 |
63 |
Allogeneic stem cell therapy |
- |
- |
- |
- |
1件: 96 |
64 |
Allogenic eascs 5 million cells/ml suspension for injection cx601 |
- |
- |
- |
- |
1件: 96 |
65 |
Allogenic eascs 5 million cells/ml suspension for injection. cx601 |
- |
- |
- |
- |
1件: 96 |
66 |
Allopurinol |
Allopurinol |
D00224 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
6件: 6, 46, 57, 66, 96, 97 |
67 |
Allopurinol sandoz 100 mg, tabletten |
Allopurinol |
D00224 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
1件: 96 |
68 |
Allopurinol sodium |
Allopurinol |
D00224 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
1件: 96 |
69 |
Alx-0600 |
- |
- |
- |
- |
1件: 96 |
70 |
Amg 139 |
- |
- |
- |
- |
1件: 96 |
71 |
Amg 181 |
- |
- |
- |
- |
2件: 96, 97 |
72 |
Amg 827 |
- |
- |
- |
- |
2件: 46, 96 |
73 |
Amg 827 210 mg |
- |
- |
- |
- |
2件: 46, 96 |
74 |
Amg 827 350 mg |
- |
- |
- |
- |
1件: 96 |
75 |
Amg 827 700 mg |
- |
- |
- |
- |
1件: 96 |
76 |
Amgevita 40mg solution for injection |
- |
- |
- |
- |
2件: 96, 97 |
77 |
Aminosalicylic acid |
Aminosalicylic acid |
D00162 |
- |
- |
2件: 96, 97 |
78 |
Ammonium chloride |
Ammonium chloride |
D01139 |
- |
- |
1件: 96 |
79 |
Amoxicillin |
Amoxicillin |
D00229, D02925, D07452 |
- |
- |
6件: 6, 46, 63, 96, 97, 222 |
80 |
An100226 |
- |
- |
- |
- |
2件: 13, 96 |
81 |
Andecaliximab |
- |
- |
- |
- |
3件: 46, 96, 299 |
82 |
Andosan |
- |
- |
- |
- |
2件: 96, 97 |
83 |
Anti tnf alfa. |
- |
- |
- |
- |
1件: 96 |
84 |
Anti tnf humanized antibody fab fragment-peg conjugate |
- |
- |
- |
- |
1件: 96 |
85 |
Anti tnf therapy including infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
86 |
Anti-cd3 |
Muromonab |
D05092 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
2件: 96, 97 |
87 |
Anti-cd3 monoclonal antibody |
Muromonab |
D05092 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
2件: 96, 97 |
88 |
Anti-il-12 |
- |
- |
- |
- |
2件: 13, 96 |
89 |
Anti-interferon-gamma monoclonal antibody |
- |
- |
- |
- |
1件: 96 |
90 |
Anti-madcam antibody |
- |
- |
- |
- |
2件: 96, 97 |
91 |
Anti-tnf |
- |
- |
- |
- |
3件: 46, 96, 271 |
92 |
Anti-tnf discontinuation: physiological saline solution |
- |
- |
- |
- |
2件: 96, 97 |
93 |
Anti-tnf drug |
- |
- |
- |
- |
2件: 96, 97 |
94 |
Anti-tnf therapy |
- |
- |
- |
- |
3件: 46, 96, 97 |
95 |
Anti-tnf: infliximab (infusion) |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
96 |
Anti-tnf:adalimumab (subcutaneus) |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
97 |
Apd334 |
- |
- |
- |
- |
4件: 93, 96, 97, 269 |
98 |
Apd371 |
- |
- |
- |
- |
1件: 96 |
99 |
Apixaban |
Apixaban |
D03213 |
1件: F10 |
1件: Complement and coagulation cascades |
2件: 96, 97 |
100 |
Apixaban 2.5 milligram |
Apixaban |
D03213 |
1件: F10 |
1件: Complement and coagulation cascades |
2件: 96, 97 |
101 |
Application of adalimumab |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
102 |
Ast-120 |
- |
- |
- |
- |
2件: 96, 97 |
103 |
Atorvastatin |
Atorvastatin |
D00258, D00887, D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
104 |
Autologous cd34-selected peripheral blood stem cells transplant |
- |
- |
- |
- |
1件: 96 |
105 |
Autologous mesenchymal stromal cell |
- |
- |
- |
- |
2件: 96, 298 |
106 |
Autologous ovalbumin-specific type 1 regulatory t lymphocytes expanded population |
- |
- |
- |
- |
1件: 96 |
107 |
Autologous stem cell transplantation |
- |
- |
- |
- |
2件: 56, 96 |
108 |
Azathioprin-ratiopharm 25mg filmtabletten |
- |
- |
- |
- |
1件: 96 |
109 |
Azathioprin-ratiopharm 50 mg filmtabletten |
- |
- |
- |
- |
1件: 96 |
110 |
Azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
18件: 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
111 |
Azathioprine (aza) or 6-mercaptopurine (6-mp) |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 96, 97 |
112 |
Azathioprine in case of endoscopic recurrence |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 96 |
113 |
Azathioprine individualised dose |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 96 |
114 |
Azathioprine or 6-mercaptopurine |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 96, 97 |
115 |
Azathioprine or adalimumab and infliximab |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 96 |
116 |
Azathioprine or mesalazine |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 96 |
117 |
Azathioprine or methotrexate |
Azathioprine, Methotrexate |
D00142, D00238, D02115, D03033 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
1件: 96 |
118 |
Azathioprine weight-based dose |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 96 |
119 |
Azathioprine+enteral nutrition |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 96 |
120 |
Azatioprina |
Azathioprine |
D00238, D03033 |
- |
- |
3件: 13, 96, 97 |
121 |
Azd9056 |
Azd9056 |
- |
- |
- |
2件: 46, 96 |
122 |
Azithromycin |
Azithromycin |
D02134, D06390, D07486 |
- |
- |
6件: 13, 84, 85, 96, 228, 299 |
123 |
Azithromycin + metronidazole |
Metronidazole |
D00409, D05016, D05017 |
- |
- |
1件: 96 |
124 |
B. theta |
- |
- |
- |
- |
1件: 96 |
125 |
Bacteriophage preparation |
- |
- |
- |
- |
1件: 96 |
126 |
Bacteriotherapy |
- |
- |
- |
- |
2件: 96, 97 |
127 |
Bean |
Bean |
- |
- |
- |
1件: 96 |
128 |
Beta carotene |
Beta carotene |
D03101 |
- |
- |
1件: 96 |
129 |
Beta carotene from dunaliella algae |
Beta carotene |
D03101 |
- |
- |
1件: 96 |
130 |
Betamethasone |
Betamethasone |
D00244, D00972, D01357, D01402, D01637, D02032, D02286 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
6件: 2, 46, 65, 90, 96, 235 |
131 |
Bfahf-2 |
- |
- |
- |
- |
1件: 96 |
132 |
Bi 655066 |
- |
- |
- |
- |
2件: 96, 271 |
133 |
Bi 655066 10 mg/ml |
- |
- |
- |
- |
1件: 96 |
134 |
Bi 655066 90 mg/ml |
- |
- |
- |
- |
2件: 96, 271 |
135 |
Bi 655130 |
- |
- |
- |
- |
3件: 37, 96, 97 |
136 |
Bi 695501 |
- |
- |
- |
- |
2件: 46, 96 |
137 |
Bibr 796 bs, 20 mg |
- |
- |
- |
- |
1件: 96 |
138 |
Bibr 796 bs, 5 mg |
- |
- |
- |
- |
1件: 96 |
139 |
Bifidobacterium infantis |
Bifidobacterium longum infantis |
- |
- |
- |
2件: 96, 97 |
140 |
Bifidobacterium infantis 35624 |
Bifidobacterium longum infantis |
- |
- |
- |
2件: 96, 97 |
141 |
Biological samplings |
- |
- |
- |
- |
1件: 96 |
142 |
Biosimilar |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
143 |
Biosimilar infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 97 |
144 |
Bli-1300 high dose |
- |
- |
- |
- |
1件: 96 |
145 |
Bli-1300 low dose |
- |
- |
- |
- |
1件: 96 |
146 |
Blood and stools samples |
- |
- |
- |
- |
1件: 96 |
147 |
Blood sampling |
- |
- |
- |
- |
4件: 13, 19, 51, 96 |
148 |
Bms-188667 |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
6件: 46, 49, 65, 96, 97, 271 |
149 |
Bms-936557 (anti-ip-10 antibody) |
- |
- |
- |
- |
1件: 96 |
150 |
Bms-945429 |
Clazakizumab |
D10312 |
- |
- |
2件: 46, 96 |
151 |
Bms-986165 |
- |
- |
- |
- |
3件: 49, 96, 97 |
152 |
Bms986165 |
- |
- |
- |
- |
1件: 96 |
153 |
Bone marrow derived mesenchymal stem cells (mscs) |
- |
- |
- |
- |
1件: 96 |
154 |
Boulardii |
- |
- |
- |
- |
2件: 96, 97 |
155 |
Brazikumab |
- |
- |
- |
- |
2件: 96, 97 |
156 |
Brazikumab high dose |
- |
- |
- |
- |
1件: 96 |
157 |
Brazikumab low dose |
- |
- |
- |
- |
1件: 96 |
158 |
Bt-11 1,000 mg |
- |
- |
- |
- |
1件: 96 |
159 |
Bt-11 active |
- |
- |
- |
- |
2件: 96, 97 |
160 |
Budenofalk |
- |
- |
- |
- |
1件: 96 |
161 |
Budenofalk 3mg gastro-resistant capsules |
- |
- |
- |
- |
1件: 96 |
162 |
Budenofalk 9mg gastro-resistant granules |
- |
- |
- |
- |
1件: 96 |
163 |
Budesonide |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
9件: 66, 93, 94, 95, 96, 97, 98, 228, 299 |
164 |
Budesonide ( zentacort capsules 3mg ) |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 96 |
165 |
Bupivacaine |
Bupivacaine |
D01450, D07552 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
7件: 46, 53, 70, 96, 168, 226, 298 |
166 |
Bupivacaine/epinephrine/dexamethasone |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 96 |
167 |
Bupropion |
Bupropion |
D00817, D07591, D07938 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
2件: 8, 96 |
168 |
C326, il-6 inhibitory avimer protein |
- |
- |
- |
- |
1件: 96 |
169 |
Caffeine |
Caffeine |
D00528, D01453 |
11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
6件: 2, 6, 46, 78, 96, 97 |
170 |
Caffeine 100 mg |
Caffeine |
D00528, D01453 |
11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 96 |
171 |
Calcitonin nasal spray (salmon) |
- |
- |
- |
- |
2件: 96, 97 |
172 |
Calcitriol |
Calcitriol |
D00129 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
8件: 37, 46, 49, 66, 96, 158, 235, 326 |
173 |
Calcium |
Calcium |
- |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
174 |
Calcium carbonate |
Calcium carbonate |
D00932, D10802 |
- |
- |
7件: 13, 19, 46, 75, 96, 235, 299 |
175 |
Cannabidiol |
Cannabidiol |
D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
13件: 6, 13, 46, 95, 96, 97, 140, 144, 145, 157, 158, 193, 271 |
176 |
Cannabis |
Medical cannabis |
- |
- |
- |
6件: 2, 6, 13, 90, 96, 97 |
177 |
Cannabis, medical |
Medical cannabis |
- |
- |
- |
5件: 2, 6, 13, 96, 97 |
178 |
Carbon |
Activated charcoal |
D03251 |
- |
- |
7件: 6, 46, 85, 86, 96, 97, 298 |
179 |
Carbonate |
Carbonate ion |
- |
- |
- |
10件: 2, 13, 17, 19, 46, 75, 96, 127, 235, 299 |
180 |
Carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
8件: 5, 13, 58, 96, 97, 265, 298, 316 |
181 |
Cc-5013 |
Lenalidomide |
D04687 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 28, 96 |
182 |
Ccx282-b |
- |
- |
- |
- |
1件: 96 |
183 |
Cdp6038 |
- |
- |
- |
- |
2件: 46, 96 |
184 |
Cdp870 |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 271 |
185 |
Celebrex |
Celecoxib |
D00567 |
1件: PTGS2 |
20件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
3件: 46, 96, 271 |
186 |
Certican |
Everolimus |
D02714 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
2件: 96, 228 |
187 |
Certolizumab |
- |
- |
- |
- |
3件: 46, 96, 271 |
188 |
Certolizumab pegol |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
6件: 37, 46, 96, 97, 226, 271 |
189 |
Certolizumab pegol (cdp870) |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
190 |
Certolizumab pegol (czp) |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 271 |
191 |
Certolizumab pegol (rinn) |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
192 |
Certolizumab pegol 400 mg |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
193 |
Chadox2 hav |
- |
- |
- |
- |
1件: 96 |
194 |
Chenodeoxycholic acid |
Chenodeoxycholic acid |
D00163 |
1件: NR1H4 |
1件: Bile secretion |
4件: 20, 96, 234, 263 |
195 |
Chenodiol |
Chenodeoxycholic acid |
D00163 |
1件: NR1H4 |
1件: Bile secretion |
1件: 96 |
196 |
Chenofalk |
Chenodeoxycholic acid |
D00163 |
1件: NR1H4 |
1件: Bile secretion |
1件: 96 |
197 |
Chloride |
Chloride ion |
- |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
198 |
Cholecalciferol |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
9件: 13, 19, 34, 46, 49, 96, 97, 298, 299 |
199 |
Cholecalciferol 10,000 iu |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 96 |
200 |
Cholecalciferol 400 iu |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 96 |
201 |
Cholecalciferol concentrate |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 96 |
202 |
Chondroitin sulfate |
Chondroitin sulfate |
D00080 |
- |
- |
2件: 96, 226 |
203 |
Cimzia |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
4件: 46, 96, 97, 271 |
204 |
Cimzia 200 mg solution for injection |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 46, 96 |
205 |
Ciprofloxacin |
Ciprofloxacin |
D00186, D02216 |
- |
- |
5件: 2, 60, 96, 97, 299 |
206 |
Ciprofloxacin hydrochloride |
Ciprofloxacin |
D00186, D02216 |
- |
- |
2件: 96, 299 |
207 |
Clarithromycin |
Clarithromycin |
D00276 |
- |
- |
8件: 6, 63, 84, 96, 97, 222, 228, 299 |
208 |
Clofarabine |
Clofarabine |
D03546 |
3件: POLA1, POLA2, RRM1 |
6件: DNA replication, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 |
209 |
Clofazimine |
Clofazimine |
D00278 |
- |
- |
1件: 96 |
210 |
Cnto 1275 |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
2件: 13, 96 |
211 |
Cnto1275 |
- |
- |
- |
- |
3件: 46, 84, 96 |
212 |
Cnto1959 |
- |
- |
- |
- |
1件: 96 |
213 |
Colecalciferol |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
4件: 13, 46, 96, 228 |
214 |
Colesevelam |
Colesevelam |
D03582, D07743 |
- |
- |
2件: 96, 260 |
215 |
Colony-purified bacteroides thetaiotaomicron (b.theta) |
- |
- |
- |
- |
1件: 96 |
216 |
Cortecosteroid |
- |
- |
- |
- |
1件: 96 |
217 |
Corticosteroid |
- |
- |
- |
- |
10件: 13, 42, 43, 44, 45, 66, 84, 96, 97, 222 |
218 |
Cosmofer |
- |
- |
- |
- |
2件: 96, 97 |
219 |
Cosmofer 50mg/ml solution for infusion or injection |
- |
- |
- |
- |
2件: 96, 97 |
220 |
Cp-461 |
- |
- |
- |
- |
1件: 96 |
221 |
Cp-690,550 |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
222 |
Cp-690,550-10 |
- |
- |
- |
- |
3件: 46, 96, 97 |
223 |
Cpsi-2364 |
- |
- |
- |
- |
1件: 96 |
224 |
Crohn's disease |
- |
- |
- |
- |
1件: 96 |
225 |
Crohns disease exclusion diet + pen |
- |
- |
- |
- |
1件: 96 |
226 |
Crown |
- |
- |
- |
- |
1件: 96 |
227 |
Ct-p13 |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
228 |
Ct-p13 sc (infliximab) |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
229 |
Ctla4ig |
- |
- |
- |
- |
4件: 46, 49, 96, 271 |
230 |
Curcumin |
Curcumin |
- |
- |
- |
10件: 13, 46, 49, 67, 74, 94, 96, 97, 139, 299 |
231 |
Cx601 |
- |
- |
- |
- |
1件: 96 |
232 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
233 |
D9421-c |
- |
- |
- |
- |
1件: 96 |
234 |
D9421-c capsule 3 mg |
- |
- |
- |
- |
1件: 96 |
235 |
D9421-c, 15mg |
- |
- |
- |
- |
1件: 96 |
236 |
D9421-c, 9mg |
- |
- |
- |
- |
1件: 96 |
237 |
Darvadstrocel |
- |
- |
- |
- |
1件: 96 |
238 |
Db adalimumab 40 mg eow |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
239 |
Db adalimumab 40 mg ew |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
240 |
Decortin |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
5件: 46, 96, 97, 113, 145 |
241 |
Decortin 20 mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 96 |
242 |
Decortin 5 mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 96 |
243 |
Dehydroepiandrosterone |
Prasterone |
D08409 |
3件: AR, ESR1, ESR2 |
11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
5件: 49, 53, 83, 96, 113 |
244 |
Dehydroepiandrosterone [dhea] |
Prasterone |
D08409 |
3件: AR, ESR1, ESR2 |
11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
1件: 96 |
245 |
Dekristol 20.000 ie |
- |
- |
- |
- |
1件: 96 |
246 |
Delayed release 6 mercaptopurine |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
1件: 96 |
247 |
Delayed release 6mp or calcitriol vs. purinethol |
Calcitriol |
D00129 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 96 |
248 |
Denosumab |
Denosumab |
D03684 |
1件: TNFSF11 |
7件: Breast cancer, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis |
7件: 46, 50, 93, 95, 96, 274, 299 |
249 |
Dexamethasone |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
20件: 13, 16, 28, 35, 46, 53, 63, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 222, 296, 299 |
250 |
Dexamethasone sodium phosphate |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 65, 96 |
251 |
Dexamethasone sodium phosphate 250 mg/ 10 ml |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 96 |
252 |
Dextran |
Dextran |
D00060 |
- |
- |
5件: 2, 62, 79, 96, 97 |
253 |
Dextromethorphan |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
9件: 2, 6, 8, 13, 46, 78, 96, 97, 156 |
254 |
Dextromethorphan 30 mg |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 96 |
255 |
Dhea |
Prasterone |
D08409 |
3件: AR, ESR1, ESR2 |
11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
3件: 49, 86, 96 |
256 |
Diet 1 |
- |
- |
- |
- |
1件: 96 |
257 |
Diet 2 |
- |
- |
- |
- |
1件: 96 |
258 |
Dietary therapy |
- |
- |
- |
- |
1件: 96 |
259 |
Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphtalen-2-ylmethyl]-ammonium chloride mon |
Ammonium chloride |
D01139 |
- |
- |
1件: 96 |
260 |
Diflucan |
Fluconazole |
D00322, D01429 |
- |
- |
1件: 96 |
261 |
Dlx105 |
- |
- |
- |
- |
1件: 96 |
262 |
Doxycycline |
Doxycycline |
D00307, D02129, D03903, D03904, D07876 |
- |
- |
15件: 13, 23, 28, 46, 84, 85, 89, 96, 97, 158, 162, 167, 227, 280, 299 |
263 |
Doxycycline hyclate |
Doxycycline |
D00307, D02129, D03903, D03904, D07876 |
- |
- |
3件: 23, 96, 227 |
264 |
E-device |
- |
- |
- |
- |
3件: 46, 96, 271 |
265 |
E6011 |
- |
- |
- |
- |
3件: 46, 93, 96 |
266 |
E6011 10 mg/kg |
- |
- |
- |
- |
1件: 96 |
267 |
E6011 15 mg/kg |
- |
- |
- |
- |
1件: 96 |
268 |
E6011 2 mg/kg |
- |
- |
- |
- |
1件: 96 |
269 |
E6011 5 mg/kg |
- |
- |
- |
- |
1件: 96 |
270 |
Early immunosuppressants (azathioprine, methotrexate) |
Azathioprine, Methotrexate |
D00142, D00238, D02115, D03033 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
1件: 96 |
271 |
Eb8018 (first-in-class fimh blocker) |
- |
- |
- |
- |
1件: 96 |
272 |
Efalizumab |
Efalizumab |
D03959 |
1件: ITGAL |
11件: Cell adhesion molecules (CAMs), Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis |
8件: 11, 13, 37, 46, 53, 61, 95, 96 |
273 |
Eicosapentaenoic acid |
Icosapent |
D08061 |
- |
- |
5件: 49, 96, 97, 296, 297 |
274 |
Entecavir |
Entecavir |
D04008, D07896 |
- |
- |
5件: 46, 56, 96, 97, 271 |
275 |
Enteral nutrition |
- |
- |
- |
- |
1件: 96 |
276 |
Enteral nutrition. |
- |
- |
- |
- |
1件: 96 |
277 |
Entocort |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 96 |
278 |
Entocort cr |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 96 |
279 |
Entocort® kapseln |
- |
- |
- |
- |
1件: 96 |
280 |
Entyvio |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
281 |
Epanova |
Omega-3-carboxylic acids |
- |
- |
- |
1件: 96 |
282 |
Epanova™ (omega-3 free fatty acids) |
Omega-3 fatty acids |
- |
- |
- |
1件: 96 |
283 |
Epaxal berna (virosomal hepatitis a vaccine) |
Hepatitis a vaccine |
- |
- |
- |
2件: 96, 97 |
284 |
Epinephrine |
Epinephrine |
D00095, D00996, D02149 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 46, 96 |
285 |
Erb-041 |
- |
- |
- |
- |
3件: 46, 96, 226 |
286 |
Ergocalciferol |
Ergocalciferol |
D00187 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
5件: 46, 84, 96, 97, 299 |
287 |
Ery-dex |
- |
- |
- |
- |
1件: 96 |
288 |
Erythropoietin |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
8件: 2, 6, 13, 22, 47, 70, 95, 96 |
289 |
Eskazole |
Albendazole |
D00134 |
- |
- |
1件: 96 |
290 |
Etiprednol dicloacetate |
Etiprednol dicloacetate |
D04100 |
- |
- |
1件: 96 |
291 |
Etrolizumab |
Etrolizumab |
D09901 |
1件: ITGB7 |
11件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer |
2件: 96, 97 |
292 |
Eu/1/99/116/003 |
- |
- |
- |
- |
1件: 96 |
293 |
Evaluation of biological predictive factors of clinical response to ustekinumab |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
294 |
Everolimus |
Everolimus |
D02714 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
8件: 34, 67, 89, 96, 137, 157, 158, 277 |
295 |
Exclusive enteral nutrition |
- |
- |
- |
- |
1件: 96 |
296 |
Exclusive enteral nutrition therapy |
- |
- |
- |
- |
1件: 96 |
297 |
Expanded allogenic adipose-derived adult stem cells |
- |
- |
- |
- |
1件: 96 |
298 |
Expanded autologous adipose-derived adult stem cells (eascs) |
- |
- |
- |
- |
1件: 96 |
299 |
Expanded human allogenic mesenchymal adult stem cells extracted from adipose tissue (eascs) |
- |
- |
- |
- |
1件: 96 |
300 |
Faecal microbiota transplantation |
- |
- |
- |
- |
2件: 96, 97 |
301 |
Fe 999301 |
- |
- |
- |
- |
2件: 96, 97 |
302 |
Fecal microbial transplant |
- |
- |
- |
- |
2件: 96, 97 |
303 |
Fecal microbial transplantation |
- |
- |
- |
- |
2件: 96, 97 |
304 |
Fecal microbiota transplant |
- |
- |
- |
- |
2件: 96, 97 |
305 |
Fecal microbiota transplant (fmt) |
- |
- |
- |
- |
1件: 96 |
306 |
Fecal microbiota transplantation |
- |
- |
- |
- |
5件: 2, 66, 94, 96, 97 |
307 |
Fecal microbiota transplantation (fmt) |
- |
- |
- |
- |
2件: 96, 97 |
308 |
Ferric carboxy maltose |
Maltose |
D00044 |
- |
- |
1件: 96 |
309 |
Ferric carboxymaltose |
Ferric carboxymaltose |
D08920 |
- |
- |
4件: 86, 96, 97, 299 |
310 |
Ferric maltol |
- |
- |
- |
- |
1件: 96 |
311 |
Ferrous sulphate |
- |
- |
- |
- |
2件: 96, 97 |
312 |
Ffp104 |
- |
- |
- |
- |
2件: 93, 96 |
313 |
Filgotinib |
Filgotinib |
D10871 |
1件: JAK1 |
26件: EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
6件: 46, 53, 96, 97, 222, 271 |
314 |
Filgrastim |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
25件: 2, 6, 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 283, 284, 285, 331 |
315 |
Fish oil |
Fish oil |
- |
- |
- |
7件: 13, 46, 49, 66, 96, 260, 299 |
316 |
Fitc-adalimumab |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
317 |
Flagyl |
Metronidazole |
D00409, D05016, D05017 |
- |
- |
2件: 96, 97 |
318 |
Fluconazole |
Fluconazole |
D00322, D01429 |
- |
- |
1件: 96 |
319 |
Fludarabine |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
17件: 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 326 |
320 |
Fludarabine phosphate |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
11件: 28, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285 |
321 |
Fluorine f 18 |
- |
- |
- |
- |
4件: 40, 46, 49, 96 |
322 |
Folatescan (technetium tc 99mec20) |
- |
- |
- |
- |
4件: 13, 46, 49, 96 |
323 |
Fosfomycin |
Fosfomycin |
D00925, D02187, D02188, D04253 |
- |
- |
2件: 96, 97 |
324 |
G-csf |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
12件: 6, 13, 16, 49, 51, 60, 65, 85, 96, 284, 285, 331 |
325 |
G321605 |
- |
- |
- |
- |
3件: 85, 96, 97 |
326 |
Ged-0301 |
- |
- |
- |
- |
2件: 96, 97 |
327 |
Glatiramer |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
4件: 2, 13, 96, 156 |
328 |
Glatiramer acetate |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
3件: 13, 96, 156 |
329 |
Glpg0634 |
- |
- |
- |
- |
3件: 46, 96, 271 |
330 |
Glpg1205 |
Glpg1205 |
- |
- |
- |
3件: 85, 96, 97 |
331 |
Glutamine |
L-glutamine |
D00015 |
- |
- |
6件: 87, 96, 97, 113, 245, 299 |
332 |
Golimumab |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
5件: 46, 84, 96, 97, 271 |
333 |
Green tea |
Green tea leaf |
D06903 |
- |
- |
5件: 6, 17, 28, 46, 96 |
334 |
Growth hormone |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
11件: 2, 13, 19, 46, 78, 96, 191, 193, 195, 265, 299 |
335 |
Gs-6034 |
- |
- |
- |
- |
3件: 46, 96, 97 |
336 |
Gsk1070806 |
- |
- |
- |
- |
2件: 56, 96 |
337 |
Gsk1605786 |
- |
- |
- |
- |
2件: 96, 97 |
338 |
Gsk1605786 500 mg |
- |
- |
- |
- |
1件: 96 |
339 |
Gsk1605786 capsule |
- |
- |
- |
- |
1件: 96 |
340 |
Gsk1605786 chemocentryx: formulation a |
- |
- |
- |
- |
1件: 96 |
341 |
Gsk1605786 gsk direct-fill: formulation c |
- |
- |
- |
- |
1件: 96 |
342 |
Gsk1605786 gsk modified-process: formulation d |
- |
- |
- |
- |
1件: 96 |
343 |
Gsk1605786 gsk tablet: formulation e |
- |
- |
- |
- |
1件: 96 |
344 |
Gsk1605786 gsk: formulation b |
- |
- |
- |
- |
1件: 96 |
345 |
Gsk1605786a |
- |
- |
- |
- |
2件: 96, 97 |
346 |
Gsk2330811 |
- |
- |
- |
- |
2件: 51, 96 |
347 |
Guselkumab |
Guselkumab |
D10438 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
3件: 37, 96, 97 |
348 |
Hematopoietic stem cell transplantation |
- |
- |
- |
- |
12件: 11, 13, 14, 19, 20, 35, 46, 49, 51, 96, 234, 285 |
349 |
Hepatitis a vaccine |
Hepatitis a vaccine |
- |
- |
- |
3件: 46, 96, 97 |
350 |
Herpes zoster vaccine |
- |
- |
- |
- |
3件: 46, 96, 271 |
351 |
Hextend |
Hydroxyethyl starch |
D03335 |
- |
- |
2件: 96, 97 |
352 |
High oligosaccharide group |
- |
- |
- |
- |
1件: 96 |
353 |
High-dose cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
1件: 96 |
354 |
Hmpl004 |
- |
- |
- |
- |
1件: 96 |
355 |
Hmpl004-6599 |
- |
- |
- |
- |
2件: 96, 97 |
356 |
Hum291 |
- |
- |
- |
- |
2件: 96, 97 |
357 |
Human anti-il-12 antibody |
- |
- |
- |
- |
1件: 96 |
358 |
Human insulin |
Insulin human |
D00085, D03230 |
1件: INSR |
20件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway |
2件: 96, 156 |
359 |
Human monoclonal antibody (cnto 1275) to interleukin 12p-40 |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
360 |
Human placenta-derived cells pda001 intravenous infusion |
- |
- |
- |
- |
1件: 96 |
361 |
Human plasma for fractionation |
- |
- |
- |
- |
1件: 96 |
362 |
Humira |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
6件: 46, 84, 96, 97, 269, 271 |
363 |
Humira (adalimumab) |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 46, 96 |
364 |
Humira 40 mg solution for injection in pre-filled syringe |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 97 |
365 |
Humira 40mg solution for injection |
- |
- |
- |
- |
2件: 96, 97 |
366 |
Humira pre-filled pen |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
367 |
Humira® |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
4件: 46, 96, 97, 271 |
368 |
Hydroxide |
Hydroxide ion |
- |
- |
- |
4件: 46, 96, 97, 284 |
369 |
Hydroxychloroquine |
Hydroxychloroquine |
D08050 |
- |
- |
18件: 13, 41, 46, 48, 49, 53, 56, 66, 84, 89, 90, 96, 222, 234, 254, 271, 298, 299 |
370 |
Hydroxychloroquine sulphate |
Hydroxychloroquine |
D08050 |
- |
- |
1件: 96 |
371 |
Il-2 |
Human interleukin-2 |
- |
- |
- |
5件: 2, 46, 49, 56, 96 |
372 |
Immune ablation and hematopoietic stem cell support |
- |
- |
- |
- |
1件: 96 |
373 |
Immunonutrition |
- |
- |
- |
- |
1件: 96 |
374 |
Immunosuppressor/tnfalpha |
- |
- |
- |
- |
1件: 96 |
375 |
Impact |
Topramezone |
- |
- |
- |
7件: 6, 13, 46, 50, 96, 97, 299 |
376 |
Imuran |
Azathioprine |
D00238, D03033 |
- |
- |
2件: 96, 97 |
377 |
Imurel |
- |
- |
- |
- |
2件: 96, 97 |
378 |
Increlex |
Mecasermin |
D03297, D04870 |
2件: GHR, IGF1R |
33件: AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway |
3件: 65, 78, 96 |
379 |
Increlex 10mg/ml solution for injection |
Mecasermin |
D03297, D04870 |
2件: GHR, IGF1R |
33件: AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway |
1件: 96 |
380 |
Inflectra |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
381 |
Infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
22件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 95, 96, 97, 98, 162, 164, 269, 271 |
382 |
Infliximab (ifx alone) |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
383 |
Infliximab (remicade) |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 271 |
384 |
Infliximab (remicade): 100 mg of lyophilized infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
385 |
Infliximab 10 mg/kg |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 97 |
386 |
Infliximab 20 mg/kg |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
387 |
Infliximab 5 mg/kg |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
388 |
Infliximab 5 mg/kg body weight infused over 2 hours |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
389 |
Infliximab 5 mg/kg every 6 weeks |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
390 |
Infliximab 7 mg/kg every 8 weeks |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
391 |
Infliximab [infliximab biosimilar 3] |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
4件: 37, 46, 96, 97 |
392 |
Infliximab and adalimumab |
Adalimumab, Infliximab |
D02597, D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
393 |
Infliximab and azathioprine combination at week 0 |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 96 |
394 |
Infliximab and azathioprine combination at week 14 |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 96 |
395 |
Infliximab infusion |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
396 |
Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab |
Ustekinumab, Vedolizumab |
D08083, D09214 |
5件: IL12A, IL12B, IL23A, ITGA4, ITGB7 |
39件: African trypanosomiasis, Allograft rejection, Amoebiasis, Arrhythmogenic right ventricular cardiomyopathy (ARVC), C-type lectin receptor signaling pathway, Cell adhesion molecules (CAMs), Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Malaria, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Yersinia infection |
2件: 96, 97 |
397 |
Infliximab with azathioprine (iifx + aza) |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 96 |
398 |
Infliximab+azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 96 |
399 |
Infliximab, adalimumab, certolizumab pegol |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
400 |
Infliximab, azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 96 |
401 |
Infliximab-biosimilar |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
402 |
Infliximab-innovator |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
403 |
Injection of iron |
Iron |
- |
- |
- |
1件: 96 |
404 |
Innovator infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 97 |
405 |
Inositol |
Inositol |
D08079 |
- |
- |
2件: 96, 97 |
406 |
Interferon alfa |
Interferon alfa |
D03305 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
5件: 25, 26, 28, 56, 96 |
407 |
Interferon beta |
Human interferon beta |
- |
- |
- |
6件: 13, 14, 20, 26, 96, 97 |
408 |
Interferon beta-1a |
Human interferon beta |
- |
- |
- |
5件: 13, 14, 26, 96, 97 |
409 |
Interleukin 2 |
Human interleukin-2 |
- |
- |
- |
9件: 46, 49, 51, 56, 63, 95, 96, 97, 271 |
410 |
Interleukin-11 |
Oprelvekin |
D05266 |
1件: IL11RA |
3件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway |
2件: 96, 288 |
411 |
Intralipid |
Soybean oil |
D04962 |
- |
- |
1件: 96 |
412 |
Intralipid 10% |
- |
- |
- |
- |
1件: 96 |
413 |
Inulin |
Inulin |
D00171 |
- |
- |
2件: 96, 299 |
414 |
Invita d3 |
- |
- |
- |
- |
1件: 96 |
415 |
Iron |
Iron |
- |
- |
- |
7件: 13, 62, 86, 96, 97, 254, 284 |
416 |
Iron sucrose |
Sucrose |
D00025 |
- |
- |
3件: 62, 96, 97 |
417 |
Iron sulphate |
Iron |
- |
- |
- |
2件: 96, 97 |
418 |
Iron sulphate 200mg coated tablets |
Iron |
- |
- |
- |
2件: 96, 97 |
419 |
Iron supplement 300-600 mg/day |
Iron |
- |
- |
- |
2件: 96, 97 |
420 |
Iron(iii)- hydroxide dextran complex |
Dextran |
D00060 |
- |
- |
2件: 96, 97 |
421 |
Itf2357 |
- |
- |
- |
- |
3件: 96, 107, 113 |
422 |
J695 |
- |
- |
- |
- |
1件: 96 |
423 |
Jenapharm |
Acetylcysteine |
D00221 |
- |
- |
2件: 96, 97 |
424 |
Jnj-40346527 |
- |
- |
- |
- |
2件: 46, 96 |
425 |
Jnj-40346527-aac |
- |
- |
- |
- |
1件: 96 |
426 |
Jnj-64304500 |
- |
- |
- |
- |
1件: 96 |
427 |
Jnj-64304500-aaa |
- |
- |
- |
- |
1件: 96 |
428 |
Jnj-67864238 |
- |
- |
- |
- |
1件: 96 |
429 |
Kanamycin |
Kanamycin |
D00866, D03262, D07497 |
- |
- |
2件: 96, 291 |
430 |
Kenacort |
- |
- |
- |
- |
1件: 96 |
431 |
Kremezin |
- |
- |
- |
- |
2件: 96, 97 |
432 |
Kremezin®, spherical adsorptive carbon |
Activated charcoal |
D03251 |
- |
- |
2件: 96, 97 |
433 |
L-carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
6件: 13, 96, 97, 265, 298, 316 |
434 |
Lactated ringers |
- |
- |
- |
- |
2件: 96, 97 |
435 |
Lactobacillus salivarius ucc118 |
- |
- |
- |
- |
2件: 96, 97 |
436 |
Lactulose |
Lactulose |
D00352 |
- |
- |
2件: 96, 291 |
437 |
Lactulose/rhamnose solution |
Lactulose |
D00352 |
- |
- |
1件: 96 |
438 |
Lap tap bupivacaine/epinephrine |
Bupivacaine, Epinephrine |
D00095, D00996, D01450, D02149, D07552 |
14件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
15件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 96 |
439 |
Laquinimod |
Laquinimod |
- |
- |
- |
4件: 8, 13, 49, 96 |
440 |
Laquinimod cápsulas 0.5 mg |
Laquinimod |
- |
- |
- |
1件: 96 |
441 |
Ldp-02 |
- |
- |
- |
- |
1件: 96 |
442 |
Liposomal bupivacaine |
Bupivacaine |
D01450, D07552 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
2件: 70, 96 |
443 |
Longum |
Sulfametopyrazine |
D01216 |
- |
- |
1件: 96 |
444 |
Losartan |
Losartan |
D00357, D08146 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
18件: 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
445 |
Low dose naltrexone |
Naltrexone |
D02095, D05113 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
2件: 96, 97 |
446 |
Low-dose il-2 administration |
Human interleukin-2 |
- |
- |
- |
1件: 96 |
447 |
Lumbar puncture |
- |
- |
- |
- |
3件: 13, 96, 97 |
448 |
Maltodextrin |
Maltodextrin |
D02329 |
- |
- |
4件: 6, 13, 96, 97 |
449 |
Maltose |
Maltose |
D00044 |
- |
- |
2件: 96, 97 |
450 |
Mannitol |
Mannitol |
D00062 |
- |
- |
3件: 6, 96, 299 |
451 |
Mare´s milk |
- |
- |
- |
- |
2件: 96, 97 |
452 |
Masitinib |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
453 |
Masitinib mesylate |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
454 |
Mb-102 |
- |
- |
- |
- |
1件: 96 |
455 |
Mdgn-002 |
- |
- |
- |
- |
1件: 96 |
456 |
Mecasermin |
Mecasermin |
D03297, D04870 |
2件: GHR, IGF1R |
33件: AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway |
5件: 78, 96, 168, 265, 299 |
457 |
Mecasermin [rdna origin] 10mg/ml solution |
Mecasermin |
D03297, D04870 |
2件: GHR, IGF1R |
33件: AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway |
1件: 96 |
458 |
Medi2070 |
- |
- |
- |
- |
1件: 96 |
459 |
Medi2070 high dose |
- |
- |
- |
- |
1件: 96 |
460 |
Medi2070 high-med dose |
- |
- |
- |
- |
1件: 96 |
461 |
Medi2070 low dose |
- |
- |
- |
- |
1件: 96 |
462 |
Medi2070 low-med dose |
- |
- |
- |
- |
1件: 96 |
463 |
Melphalan |
Melphalan |
D00369 |
- |
- |
14件: 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285 |
464 |
Mensa |
- |
- |
- |
- |
1件: 96 |
465 |
Mercaptopurine |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
3件: 96, 97, 164 |
466 |
Mesalamine |
Mesalazine |
D00377 |
- |
- |
3件: 96, 97, 164 |
467 |
Mesalamine, 5-aminosalicylic acid |
Aminosalicylic acid |
D00162 |
- |
- |
1件: 96 |
468 |
Mesalazine |
Mesalazine |
D00377 |
- |
- |
3件: 46, 96, 97 |
469 |
Mesalazine (mesalamine) |
Mesalazine |
D00377 |
- |
- |
1件: 96 |
470 |
Mesalazine ec 500 mg |
Mesalazine |
D00377 |
- |
- |
1件: 96 |
471 |
Mesalazine sustained-release tablets |
Mesalazine |
D00377 |
- |
- |
1件: 96 |
472 |
Mesalazine tablets |
Mesalazine |
D00377 |
- |
- |
1件: 96 |
473 |
Mesalazine, tripterygium glycosides |
Mesalazine |
D00377 |
- |
- |
1件: 96 |
474 |
Mesenchymal cell and fibroblast injection |
- |
- |
- |
- |
1件: 96 |
475 |
Mesenchymal cell transplantation |
- |
- |
- |
- |
2件: 46, 96 |
476 |
Mesenchymal stem cells |
- |
- |
- |
- |
11件: 2, 6, 13, 20, 49, 51, 60, 96, 222, 274, 299 |
477 |
Mesenchymal stem cells (msc) |
- |
- |
- |
- |
1件: 96 |
478 |
Mesenchymal stem cells (mscs) |
- |
- |
- |
- |
3件: 13, 36, 96 |
479 |
Mesenchymal stromal cells |
- |
- |
- |
- |
6件: 36, 51, 96, 97, 274, 284 |
480 |
Mesenchymal stromal cells (msc) for infusion |
- |
- |
- |
- |
1件: 96 |
481 |
Mesna |
Coenzyme m |
- |
- |
- |
9件: 13, 44, 45, 49, 51, 60, 65, 96, 164 |
482 |
Methacholine |
Methacholine |
- |
- |
- |
1件: 96 |
483 |
Methotrexate |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
484 |
Methoxsalen |
Methoxsalen |
D00139 |
- |
- |
3件: 36, 46, 96 |
485 |
Methoxsalen +ecp |
Methoxsalen |
D00139 |
- |
- |
1件: 96 |
486 |
Methyl prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
3件: 43, 49, 96 |
487 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
488 |
Methylprednisolone or budesonide |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 96 |
489 |
Metronidazol |
Metronidazole |
D00409, D05016, D05017 |
- |
- |
2件: 46, 96 |
490 |
Metronidazole |
Metronidazole |
D00409, D05016, D05017 |
- |
- |
8件: 46, 51, 63, 94, 95, 96, 97, 291 |
491 |
Microbiota |
- |
- |
- |
- |
1件: 96 |
492 |
Midazolam |
Midazolam |
D00550, D00696, D05028 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
10件: 2, 3, 6, 13, 46, 70, 96, 97, 231, 298 |
493 |
Midazolam 2 mg |
Midazolam |
D00550, D00696, D05028 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 96 |
494 |
Midazolam 3 mg |
Midazolam |
D00550, D00696, D05028 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 96 |
495 |
Mirikizumab |
Mirikizumab |
D11123 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
2件: 96, 97 |
496 |
Mln0002 |
- |
- |
- |
- |
2件: 96, 97 |
497 |
Mln0002 (vedolizumab) |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
498 |
Mln002 |
- |
- |
- |
- |
2件: 96, 97 |
499 |
Mobilization of stem cells to prepare for leukapheresis |
- |
- |
- |
- |
1件: 96 |
500 |
Moderate oligosaccharide group |
- |
- |
- |
- |
1件: 96 |
501 |
Modulen ibd |
- |
- |
- |
- |
1件: 96 |
502 |
Modulen ibd (r) (specific enteral nutrition) |
- |
- |
- |
- |
1件: 96 |
503 |
Mongersen |
Mongersen |
D10956 |
1件: SMAD7 |
2件: Hippo signaling pathway, TGF-beta signaling pathway |
2件: 96, 97 |
504 |
Monoclonal antibody anti-igg1 |
- |
- |
- |
- |
3件: 37, 96, 97 |
505 |
Monoclonal antibody ca2 |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
506 |
Mosapride |
Mosapride |
D08236 |
1件: HTR4 |
4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, cAMP signaling pathway |
1件: 96 |
507 |
Msc injection 01 |
- |
- |
- |
- |
1件: 96 |
508 |
Msc injection 02 |
- |
- |
- |
- |
1件: 96 |
509 |
Msc treatment 01 |
- |
- |
- |
- |
1件: 96 |
510 |
Msc treatment 02 |
- |
- |
- |
- |
1件: 96 |
511 |
Msc-afp |
- |
- |
- |
- |
1件: 96 |
512 |
Mt-1303 |
- |
- |
- |
- |
2件: 13, 96 |
513 |
Mva hav |
- |
- |
- |
- |
1件: 96 |
514 |
Mycophenolate |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
33件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
515 |
Mycophenolate mofetil |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
516 |
Mycophenolic acid |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
7件: 11, 49, 51, 60, 66, 96, 222 |
517 |
Naltrexone |
Naltrexone |
D02095, D05113 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
518 |
Naltrexone-hcl |
Naltrexone |
D02095, D05113 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
1件: 96 |
519 |
Natalizumab |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
4件: 13, 15, 46, 96 |
520 |
Neomycin |
Neomycin |
D08260 |
- |
- |
3件: 96, 97, 296 |
521 |
Ni-0401 (anti-cd3 mab) |
Muromonab |
D05092 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
1件: 96 |
522 |
Nitazoxanide |
Nitazoxanide |
D02486 |
- |
- |
2件: 96, 97 |
523 |
Nivolumab |
Nivolumab |
D10316 |
1件: PDCD1 |
3件: Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway |
10件: 13, 26, 41, 46, 49, 50, 51, 53, 96, 97 |
524 |
Nnc 0142-0000-0002 |
- |
- |
- |
- |
2件: 46, 96 |
525 |
Nnc0142-0000-0002 |
- |
- |
- |
- |
1件: 96 |
526 |
Nnc142-0002 |
- |
- |
- |
- |
1件: 96 |
527 |
None |
- |
- |
- |
- |
8件: 46, 78, 84, 96, 160, 161, 171, 299 |
528 |
Normal saline |
- |
- |
- |
- |
14件: 6, 17, 22, 36, 46, 49, 60, 94, 96, 211, 226, 276, 296, 299 |
529 |
Null |
- |
- |
- |
- |
17件: 6, 13, 14, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
530 |
Nutraceutical combination |
- |
- |
- |
- |
1件: 96 |
531 |
Nutrition treat |
- |
- |
- |
- |
1件: 96 |
532 |
Nutropinaq 10mg/2ml solution for injection |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
1件: 96 |
533 |
Nutropinaq® |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
1件: 96 |
534 |
Ol adalimumab 40 mg |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
535 |
Oligofructose enriched inulin |
Inulin |
D00171 |
- |
- |
1件: 96 |
536 |
Olokizumab |
Olokizumab |
- |
- |
- |
2件: 46, 96 |
537 |
Omega-3 |
Omega-3 fatty acids |
- |
- |
- |
7件: 13, 46, 49, 66, 79, 96, 299 |
538 |
Omegaven |
Fish oil |
- |
- |
- |
1件: 96 |
539 |
Omeprazole |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
15件: 6, 8, 13, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
540 |
Omeprazole 20 mg |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
1件: 96 |
541 |
Omeprazole 40 mg |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
1件: 96 |
542 |
Only 1 arm: treatment with msc-afp |
- |
- |
- |
- |
1件: 96 |
543 |
Opc-6535 |
- |
- |
- |
- |
2件: 96, 97 |
544 |
Opc-6535(tetomilast) |
Tetomilast |
- |
- |
- |
2件: 96, 97 |
545 |
Ops-2071 150 mg |
- |
- |
- |
- |
1件: 96 |
546 |
Ops-2071 300 mg |
- |
- |
- |
- |
1件: 96 |
547 |
Ops-2071 600 mg |
- |
- |
- |
- |
1件: 96 |
548 |
Optison |
Human serum albumin |
D05424 |
- |
- |
1件: 96 |
549 |
Orencia |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
9件: 46, 50, 51, 53, 65, 84, 96, 97, 271 |
550 |
Originator (legacy) drug |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
551 |
Other biological agent |
- |
- |
- |
- |
2件: 46, 96 |
552 |
Ova-treg |
- |
- |
- |
- |
1件: 96 |
553 |
Ovasave |
- |
- |
- |
- |
1件: 96 |
554 |
Oxadrop |
- |
- |
- |
- |
1件: 96 |
555 |
Oxygen |
Oxygen |
D00003 |
- |
- |
14件: 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 299, 330 |
556 |
Ozanimod |
Ozanimod |
D10968 |
5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
3件: 13, 96, 97 |
557 |
Ozanimod hydrochloride |
Ozanimod |
D10968 |
5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
3件: 13, 96, 97 |
558 |
P28gst |
- |
- |
- |
- |
1件: 96 |
559 |
Pancrelipase |
Pancrelipase |
D05349 |
- |
- |
4件: 96, 97, 298, 299 |
560 |
Pda001 |
- |
- |
- |
- |
2件: 46, 96 |
561 |
Pectin |
Pectin |
D02316 |
- |
- |
1件: 96 |
562 |
Pegylated interferon alfa |
Interferon alfa |
D03305 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 96 |
563 |
Pentasa sachet |
Mesalazine |
D00377 |
- |
- |
1件: 96 |
564 |
Pentasa sachet 1 g |
Mesalazine |
D00377 |
- |
- |
1件: 96 |
565 |
Pentasa sachet 1 g prolonged release granules |
Mesalazine |
D00377 |
- |
- |
1件: 96 |
566 |
Pentoxifylline |
Pentoxifylline |
D00501 |
- |
- |
10件: 26, 56, 84, 93, 96, 113, 220, 222, 296, 298 |
567 |
Pf-00547659 |
- |
- |
- |
- |
1件: 96 |
568 |
Pf-00547659 sc injection |
- |
- |
- |
- |
2件: 96, 97 |
569 |
Pf-04236921 |
- |
- |
- |
- |
2件: 49, 96 |
570 |
Pf-04236921 sc injection |
- |
- |
- |
- |
1件: 96 |
571 |
Pf-06651600 |
- |
- |
- |
- |
3件: 46, 96, 97 |
572 |
Pf-06700841 |
- |
- |
- |
- |
3件: 49, 96, 97 |
573 |
Phosphate |
Phosphate ion |
- |
- |
- |
29件: 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
574 |
Phylloquinone |
Phylloquinone |
D00148 |
- |
- |
1件: 96 |
575 |
Phylloquinone (vitamin k1) |
Phylloquinone |
D00148 |
- |
- |
1件: 96 |
576 |
Physician standard-of-care |
- |
- |
- |
- |
1件: 96 |
577 |
Pioglitazone |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
578 |
Pioglitazone 15 mg |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
1件: 96 |
579 |
Pl 17901/0122 |
- |
- |
- |
- |
1件: 96 |
580 |
Pl 20532/0012 |
- |
- |
- |
- |
1件: 96 |
581 |
Placebo |
- |
- |
- |
- |
20件: 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
582 |
Placebo ustekinumab |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
583 |
Plaquenil |
Hydroxychloroquine |
D08050 |
- |
- |
4件: 46, 49, 53, 96 |
584 |
Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología prgf-system (bti) |
- |
- |
- |
- |
1件: 96 |
585 |
Pnemovax |
- |
- |
- |
- |
1件: 96 |
586 |
Pneumovax |
- |
- |
- |
- |
3件: 46, 49, 96 |
587 |
Polaprezinc |
Polaprezinc |
D01611 |
- |
- |
2件: 96, 97 |
588 |
Polyethylene glycol |
Polyethylene glycol |
D03370 |
- |
- |
2件: 96, 97 |
589 |
Polyethylene glycol 3350 |
Polyethylene glycol |
D03370 |
- |
- |
1件: 96 |
590 |
Pomegranate |
Pomegranate |
- |
- |
- |
2件: 96, 97 |
591 |
Pravastatin |
Pravastatin |
D00893, D08410 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
9件: 13, 46, 49, 67, 79, 96, 164, 265, 333 |
592 |
Prebiotics |
- |
- |
- |
- |
1件: 96 |
593 |
Prednisolon |
- |
- |
- |
- |
4件: 46, 66, 96, 97 |
594 |
Prednisolon jenapharm |
Acetylcysteine |
D00221 |
- |
- |
2件: 96, 97 |
595 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
596 |
Prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
43件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
597 |
Preparative regimen 4-6 weeks after leukapheresis |
- |
- |
- |
- |
1件: 96 |
598 |
Prevenar 13 |
- |
- |
- |
- |
2件: 46, 96 |
599 |
Probiotic |
- |
- |
- |
- |
5件: 2, 6, 96, 193, 266 |
600 |
Probiotic - vsl#3 |
- |
- |
- |
- |
1件: 96 |
601 |
Probiotic mixture |
- |
- |
- |
- |
2件: 96, 97 |
602 |
Probiotics |
- |
- |
- |
- |
4件: 94, 96, 97, 291 |
603 |
Prochymal (remestemcel-l) |
Remestemcel-l |
D09719 |
- |
- |
1件: 96 |
604 |
Prochymal adult human mesenchymal stem cells |
Remestemcel-l |
D09719 |
- |
- |
1件: 96 |
605 |
Prochymal™ adult human mesenchymal stem cells |
Remestemcel-l |
D09719 |
- |
- |
1件: 96 |
606 |
Promethazine |
Promethazine |
D00480, D00494, D01242, D03290 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 96 |
607 |
Prucalopride |
Prucalopride |
D09205 |
1件: HTR4 |
4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, cAMP signaling pathway |
3件: 13, 51, 96 |
608 |
Prv-6527 |
- |
- |
- |
- |
1件: 96 |
609 |
Prv-6527 (jnj-40346527) |
- |
- |
- |
- |
1件: 96 |
610 |
Prv-6527(jnj-40346527) |
- |
- |
- |
- |
1件: 96 |
611 |
Qax567 |
- |
- |
- |
- |
1件: 96 |
612 |
Qax576 |
- |
- |
- |
- |
4件: 51, 85, 96, 98 |
613 |
Qbeco |
- |
- |
- |
- |
1件: 96 |
614 |
Qbeco-ssi |
- |
- |
- |
- |
1件: 96 |
615 |
Rabbit |
Rabbit |
- |
- |
- |
7件: 13, 49, 51, 60, 65, 96, 285 |
616 |
Rabbit antithymocyte globulin |
Rabbit |
- |
- |
- |
3件: 49, 60, 96 |
617 |
Rad001 |
Everolimus |
D02714 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
5件: 34, 67, 89, 96, 158 |
618 |
Raptiva 100 mg/ml powder and solvent for solution for injection |
Efalizumab |
D03959 |
1件: ITGAL |
11件: Cell adhesion molecules (CAMs), Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis |
7件: 11, 13, 46, 53, 61, 95, 96 |
619 |
Rbatg |
- |
- |
- |
- |
2件: 51, 96 |
620 |
Rctb-401 |
- |
- |
- |
- |
1件: 96 |
621 |
Received hormone maintenance therapy |
- |
- |
- |
- |
1件: 96 |
622 |
Recombinant growth hormone |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
2件: 78, 96 |
623 |
Recombinant human insulin-like growth factor |
Insulin human |
D00085, D03230 |
1件: INSR |
20件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway |
1件: 96 |
624 |
Recombinant human interleukin-11 (rhil-11) |
Oprelvekin |
D05266 |
1件: IL11RA |
3件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway |
1件: 96 |
625 |
Remestemcel-l |
- |
- |
- |
- |
1件: 96 |
626 |
Remicade |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
8件: 46, 49, 56, 84, 85, 96, 97, 271 |
627 |
Remicade (infliximab) |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 46, 96 |
628 |
Remsima |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
4件: 46, 96, 97, 271 |
629 |
Remsima (infliximab) |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 97 |
630 |
Remsima - 100 mg polvere per concentrato per soluzione per infusione - uso endovenoso - flanconcino (vetro) - 1 flaconcino |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
4件: 46, 96, 97, 271 |
631 |
Remsima and inflectra |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
632 |
Rhamnose |
Rhamnose |
- |
- |
- |
1件: 96 |
633 |
Rhb-104 |
- |
- |
- |
- |
2件: 13, 96 |
634 |
Rhgh |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
2件: 78, 96 |
635 |
Rhigf (increlex) |
- |
- |
- |
- |
1件: 96 |
636 |
Ribavirin |
Ribavirin |
D00423 |
- |
- |
2件: 2, 96 |
637 |
Riboflavin |
Riboflavin |
D00050, D01622, D01913 |
- |
- |
8件: 13, 38, 46, 96, 97, 162, 168, 265 |
638 |
Riboflavin sodium phosphate injection |
Riboflavin |
D00050, D01622, D01913 |
- |
- |
1件: 96 |
639 |
Riboflavin supplementation |
Riboflavin |
D00050, D01622, D01913 |
- |
- |
1件: 96 |
640 |
Rifabutin |
Rifabutin |
D00424 |
- |
- |
1件: 96 |
641 |
Rifabutin, clarithromycin, and clofazimine |
Clarithromycin |
D00276 |
- |
- |
1件: 96 |
642 |
Rifaximin |
Rifaximin |
D02554 |
- |
- |
5件: 6, 96, 97, 99, 296 |
643 |
Rifaximin delayed release (dr) |
Rifaximin |
D02554 |
- |
- |
1件: 96 |
644 |
Rifaximin delayed release 400 mg film coated tablet |
Rifaximin |
D02554 |
- |
- |
1件: 96 |
645 |
Rifaximin delayed release tablets |
Rifaximin |
D02554 |
- |
- |
1件: 96 |
646 |
Rifaximin eir |
Rifaximin |
D02554 |
- |
- |
1件: 96 |
647 |
Rifaximin+omeprazole+miralax |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
1件: 96 |
648 |
Rifaximin-eir |
Rifaximin |
D02554 |
- |
- |
1件: 96 |
649 |
Rifaximina |
Rifaximin |
D02554 |
- |
- |
1件: 96 |
650 |
Risankizumab |
Risankizumab |
D11052 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
4件: 37, 96, 97, 271 |
651 |
Risankizumab iv |
Risankizumab |
D11052 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
2件: 96, 97 |
652 |
Risankizumab sc |
Risankizumab |
D11052 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
2件: 96, 97 |
653 |
Risedronate |
Risedronic acid |
D00942, D03234, D08484 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
5件: 46, 66, 96, 113, 274 |
654 |
Rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
655 |
Ro 549-0261/f04-02 |
- |
- |
- |
- |
1件: 96 |
656 |
Ro 549-0261/f08-02 |
- |
- |
- |
- |
1件: 96 |
657 |
Rosuvastatin |
Rosuvastatin |
D01915, D08492 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
8件: 6, 46, 49, 51, 79, 96, 271, 299 |
658 |
Rosuvastatin 10 mg |
Rosuvastatin |
D01915, D08492 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 96 |
659 |
Routine treatment of cd |
- |
- |
- |
- |
1件: 96 |
660 |
Rpc1063 |
- |
- |
- |
- |
3件: 13, 96, 97 |
661 |
Rpc1063 (equivalent to ozanimod hcl) |
Ozanimod |
D10968 |
5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 96 |
662 |
Rr110 (tamibarotene) |
Tamibarotene |
D01418 |
1件: RARA |
5件: Acute myeloid leukemia, Estrogen signaling pathway, Pathways in cancer, Th17 cell differentiation, Transcriptional misregulation in cancer |
1件: 96 |
663 |
Rvg 05565 |
- |
- |
- |
- |
1件: 96 |
664 |
Rvg 07151 |
- |
- |
- |
- |
1件: 96 |
665 |
Salofalk 500 mg |
Mesalazine |
D00377 |
- |
- |
1件: 96 |
666 |
Same |
Ademetionine |
D07128 |
- |
- |
15件: 6, 14, 22, 43, 44, 46, 47, 49, 50, 60, 84, 93, 96, 97, 172 |
667 |
Sandostatine |
Octreotide |
D00442, D06495 |
1件: SSTR2 |
4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 96 |
668 |
Sargramostim |
Sargramostim |
D05803 |
1件: CSF2RA |
4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
6件: 6, 28, 60, 62, 96, 229 |
669 |
Sargramostim (leukine) |
Sargramostim |
D05803 |
1件: CSF2RA |
4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
1件: 96 |
670 |
Sc12267 |
Sc12267 |
- |
- |
- |
3件: 46, 96, 97 |
671 |
Search for exocrine pancreatic insufficiency at week 0 and 12 |
- |
- |
- |
- |
1件: 96 |
672 |
Semapimod |
Semapimod |
- |
- |
- |
1件: 96 |
673 |
Shingrix |
- |
- |
- |
- |
3件: 46, 96, 97 |
674 |
Shp647 |
- |
- |
- |
- |
2件: 96, 97 |
675 |
Shr0302 |
- |
- |
- |
- |
3件: 46, 96, 97 |
676 |
Simethicone |
Simethicone |
D05841 |
- |
- |
2件: 13, 96 |
677 |
Sirolimus |
Sirolimus |
D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
30件: 13, 17, 34, 35, 36, 46, 51, 60, 62, 63, 65, 66, 67, 85, 89, 96, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 |
678 |
Sivelestat |
Sivelestat |
D03788 |
1件: ELANE |
2件: Systemic lupus erythematosus, Transcriptional misregulation in cancer |
3件: 13, 85, 96 |
679 |
Smoflipid |
Soybean oil |
D04962 |
- |
- |
1件: 96 |
680 |
Smoking cigarettes |
- |
- |
- |
- |
2件: 96, 97 |
681 |
Smoking of cannabis |
Medical cannabis |
- |
- |
- |
2件: 96, 97 |
682 |
Solid food-based intervention |
- |
- |
- |
- |
1件: 96 |
683 |
Somatropin |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
15件: 2, 3, 19, 46, 74, 75, 78, 96, 113, 193, 195, 265, 274, 276, 299 |
684 |
Somatropin [rdna origin] for injection |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
2件: 46, 96 |
685 |
Somatropin(rhgh) |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
1件: 96 |
686 |
Sonovue |
Sulfur hexafluoride |
D05962 |
- |
- |
1件: 96 |
687 |
Soy protein |
- |
- |
- |
- |
2件: 6, 96 |
688 |
Soya bean oil |
Bean |
- |
- |
- |
1件: 96 |
689 |
Spesolimab |
- |
- |
- |
- |
3件: 37, 96, 97 |
690 |
St10 |
- |
- |
- |
- |
1件: 96 |
691 |
Sta-5326 |
- |
- |
- |
- |
2件: 65, 96 |
692 |
Sta-5326 mesylate |
- |
- |
- |
- |
1件: 96 |
693 |
Sta-6838, sta-5326 m, s38 |
- |
- |
- |
- |
1件: 96 |
694 |
Stable isotope infusions |
- |
- |
- |
- |
1件: 96 |
695 |
Standard 2 hours-infusion |
- |
- |
- |
- |
2件: 96, 97 |
696 |
Standard step-up care |
- |
- |
- |
- |
1件: 96 |
697 |
Start adalimumab in monotherapy |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
698 |
Stelara |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
3件: 49, 96, 269 |
699 |
Stelara, remicade, entyvio, humira, remsima, flixabi, inflectra |
- |
- |
- |
- |
1件: 96 |
700 |
Stelara® |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
701 |
Stem cells |
- |
- |
- |
- |
4件: 2, 4, 96, 113 |
702 |
Step-up |
- |
- |
- |
- |
1件: 96 |
703 |
Steroids |
- |
- |
- |
- |
7件: 46, 50, 51, 63, 66, 96, 97 |
704 |
Stromal vascular fraction (svf) |
- |
- |
- |
- |
1件: 96 |
705 |
Sucrose |
Sucrose |
D00025 |
- |
- |
3件: 62, 96, 97 |
706 |
Sugar extract |
- |
- |
- |
- |
2件: 96, 97 |
707 |
Sulfate |
Sulfate ion |
- |
- |
- |
22件: 2, 6, 11, 13, 26, 34, 36, 46, 49, 60, 61, 64, 66, 79, 86, 96, 222, 226, 265, 296, 297, 299 |
708 |
Sulfur hexafluoride |
Sulfur hexafluoride |
D05962 |
- |
- |
1件: 96 |
709 |
Sulphur hexafluoride |
Sulfur hexafluoride |
D05962 |
- |
- |
1件: 96 |
710 |
Suspension containing 250 embryonated, viable trichuris suis ova (tso)/15ml |
- |
- |
- |
- |
1件: 96 |
711 |
Suspension containing 250 embryonated, viable tso/15ml |
- |
- |
- |
- |
1件: 96 |
712 |
Suspension containing 2500 embryonated, viable trichuris suis ova (tso)/15ml |
- |
- |
- |
- |
1件: 96 |
713 |
Suspension containing 2500 embryonated, viable tso/15ml |
- |
- |
- |
- |
1件: 96 |
714 |
Suspension containing 7500 embryonated, viable trichuris suis ova (tso)/15ml |
- |
- |
- |
- |
1件: 96 |
715 |
Suspension of 7500 embryonated, viable tso/15ml |
- |
- |
- |
- |
1件: 96 |
716 |
Synbiotic (synergy i / b.longum) |
Sulfametopyrazine |
D01216 |
- |
- |
1件: 96 |
717 |
Ta-650 |
- |
- |
- |
- |
4件: 37, 56, 96, 97 |
718 |
Tacrolimus |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
29件: 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
719 |
Tak-018 |
- |
- |
- |
- |
1件: 96 |
720 |
Tamibarotene |
Tamibarotene |
D01418 |
1件: RARA |
5件: Acute myeloid leukemia, Estrogen signaling pathway, Pathways in cancer, Th17 cell differentiation, Transcriptional misregulation in cancer |
2件: 26, 96 |
721 |
Td-1473 |
- |
- |
- |
- |
2件: 96, 97 |
722 |
Teduglutide |
Teduglutide |
D06053 |
1件: GLP2R |
1件: Neuroactive ligand-receptor interaction |
1件: 96 |
723 |
Teduglutide (alx-0600) |
Teduglutide |
D06053 |
1件: GLP2R |
1件: Neuroactive ligand-receptor interaction |
1件: 96 |
724 |
Teduglutide 0.05 |
Teduglutide |
D06053 |
1件: GLP2R |
1件: Neuroactive ligand-receptor interaction |
1件: 96 |
725 |
Teduglutide 0.05 dose |
Teduglutide |
D06053 |
1件: GLP2R |
1件: Neuroactive ligand-receptor interaction |
1件: 96 |
726 |
Teduglutide 0.1 mg dose |
Teduglutide |
D06053 |
1件: GLP2R |
1件: Neuroactive ligand-receptor interaction |
1件: 96 |
727 |
Teduglutide 0.2 mg |
Teduglutide |
D06053 |
1件: GLP2R |
1件: Neuroactive ligand-receptor interaction |
1件: 96 |
728 |
Tetomilast |
Tetomilast |
- |
- |
- |
2件: 96, 97 |
729 |
Thalidomide |
Thalidomide |
D00754 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
730 |
Thalidomide celgene - 50 mg capsula rigida - uso orale - blister (pvc/pe/aclar/alu) 28 capsule |
Thalidomide |
D00754 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
731 |
Thalidomide pharmion |
Thalidomide |
D00754 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 85, 96, 97 |
732 |
Thc 5mg/ml and cbs 50mg/ml |
- |
- |
- |
- |
1件: 96 |
733 |
Thetanix |
- |
- |
- |
- |
1件: 96 |
734 |
Thiopurine |
- |
- |
- |
- |
1件: 96 |
735 |
Thiotepa |
Thiotepa |
D00583 |
- |
- |
11件: 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284 |
736 |
Threonine |
L-threonine |
D00041 |
- |
- |
3件: 86, 96, 97 |
737 |
Thrx-139060 |
- |
- |
- |
- |
2件: 96, 97 |
738 |
Thymoglobulin |
- |
- |
- |
- |
4件: 36, 51, 60, 96 |
739 |
Ticilimumab |
Tremelimumab |
D06657 |
1件: CTLA4 |
4件: Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Rheumatoid arthritis, T cell receptor signaling pathway |
1件: 96 |
740 |
Time and attention |
- |
- |
- |
- |
1件: 96 |
741 |
Time and attention + active fructooligosaccharide supplementation |
- |
- |
- |
- |
1件: 96 |
742 |
Tnf kinoid |
- |
- |
- |
- |
1件: 96 |
743 |
Tnf-alpha antagonists |
- |
- |
- |
- |
3件: 46, 96, 271 |
744 |
Tnf-k |
- |
- |
- |
- |
2件: 46, 96 |
745 |
Tnf-kinoid |
- |
- |
- |
- |
2件: 46, 96 |
746 |
Tnfa kinoid |
- |
- |
- |
- |
1件: 96 |
747 |
Tofacitinib |
Tofacitinib |
D09970 |
4件: JAK1, JAK2, JAK3, TYK2 |
34件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
9件: 46, 49, 50, 51, 84, 96, 97, 107, 271 |
748 |
Tolerogenic dendritic cells |
- |
- |
- |
- |
2件: 46, 96 |
749 |
Top-down |
- |
- |
- |
- |
1件: 96 |
750 |
Tr004 (treg immunotherapy) |
- |
- |
- |
- |
1件: 96 |
751 |
Treatment with adalimumab |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 96 |
752 |
Triamcinolone |
Triamcinolone |
D00385, D00983, D00984, D00985, D06216 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
8件: 35, 46, 56, 70, 90, 96, 226, 298 |
753 |
Trichuris suis eggs |
- |
- |
- |
- |
3件: 13, 96, 97 |
754 |
Trichuris suis ova |
- |
- |
- |
- |
4件: 13, 46, 96, 97 |
755 |
Trichuris suis ova (tso) |
- |
- |
- |
- |
2件: 96, 97 |
756 |
Trichuris trichiura eggs |
- |
- |
- |
- |
1件: 96 |
757 |
Tripterygium |
Tripterygium wilfordii whole |
- |
- |
- |
8件: 46, 66, 67, 96, 162, 222, 224, 271 |
758 |
Tripterygium glycosides |
Tripterygium wilfordii whole |
- |
- |
- |
1件: 96 |
759 |
Trk-170 |
- |
- |
- |
- |
1件: 96 |
760 |
Tso 250 |
- |
- |
- |
- |
1件: 96 |
761 |
Tso 2500 |
- |
- |
- |
- |
1件: 96 |
762 |
Tso 7500 |
- |
- |
- |
- |
1件: 96 |
763 |
Tu-100 |
- |
- |
- |
- |
1件: 96 |
764 |
Tv-5600 |
- |
- |
- |
- |
2件: 13, 96 |
765 |
Ultrasound microbubble contrast agent |
- |
- |
- |
- |
1件: 96 |
766 |
Upadacitinib |
Upadacitinib |
D10994 |
1件: JAK1 |
26件: EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
6件: 41, 46, 49, 96, 97, 271 |
767 |
Ursodeoxycholic acid |
Ursodeoxycholic acid |
D00734 |
1件: NR1H4 |
1件: Bile secretion |
8件: 6, 67, 84, 93, 94, 95, 96, 97 |
768 |
Ursofalk |
Ursodeoxycholic acid |
D00734 |
1件: NR1H4 |
1件: Bile secretion |
4件: 93, 94, 96, 97 |
769 |
Ursofalk® 250 mg tabletten. |
- |
- |
- |
- |
1件: 96 |
770 |
Us tap bupivacaine/epinephrine |
Bupivacaine, Epinephrine |
D00095, D00996, D01450, D02149, D07552 |
14件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
15件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 96 |
771 |
Ustekinumab |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 |
772 |
Ustekinumab (6 mg/kg) |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
773 |
Ustekinumab (90 mg) |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
774 |
Ustekinumab 130 mg iv |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
775 |
Ustekinumab 1mg/kg (ip) |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
776 |
Ustekinumab 3 mg/kg (ip) |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
777 |
Ustekinumab 4.5 mg/kg |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
778 |
Ustekinumab 6 mg/kg (ip) |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
779 |
Ustekinumab 90 mg |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
3件: 50, 93, 96 |
780 |
Ustekinumab 90 mg (sc) group 1 |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
781 |
Ustekinumab 90 mg (sc) group 2 |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
782 |
Ustekinumab 90 mg sc q12w |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
783 |
Ustekinumab 90 mg sc q8w |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
784 |
Ustekinumab approximately 6 mg/kg (iv) |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
785 |
Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp) |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
786 |
Ustekinumab iv - responder - ustekinumab 90mg sc (mp) |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
787 |
Ustekinumab iv infusion |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
788 |
Ustekinumab sc injection |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 96 |
789 |
Uttr1147a |
- |
- |
- |
- |
2件: 96, 97 |
790 |
Uvadex |
Methoxsalen |
D00139 |
- |
- |
2件: 46, 96 |
791 |
Uvadex and uvar xts photopheresis system |
- |
- |
- |
- |
1件: 96 |
792 |
V565 |
- |
- |
- |
- |
1件: 96 |
793 |
Vancomycin |
Vancomycin |
D00212, D00926 |
- |
- |
7件: 46, 70, 94, 96, 97, 296, 299 |
794 |
Vedolizumab |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
795 |
Vedolizumab (genetical recombination) |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
1件: 96 |
796 |
Vedolizumab 300 mg injection [entyvio] |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
1件: 96 |
797 |
Vedolizumab intravenous injection |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
798 |
Vedolizumab iv |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
799 |
Vedolizumab iv 300 mg |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
800 |
Vedolizumab sc |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
801 |
Vedolizumab sc 108 mg |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
802 |
Vedolizumab subcutaneous injection |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
803 |
Vedolizumab-800cw |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
1件: 96 |
804 |
Vehice control |
- |
- |
- |
- |
1件: 96 |
805 |
Verapamil |
Verapamil |
D00619, D02356 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 96, 130, 140, 167 |
806 |
Viagra |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
3件: 86, 96, 225 |
807 |
Vigantol oel |
- |
- |
- |
- |
3件: 13, 96, 97 |
808 |
Vigantol oel tm |
- |
- |
- |
- |
2件: 96, 97 |
809 |
Visilizumab |
Visilizumab |
D06314 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
2件: 96, 97 |
810 |
Vitamin d |
Vitamin d |
- |
- |
- |
18件: 13, 19, 41, 46, 49, 50, 68, 93, 95, 96, 98, 179, 222, 228, 235, 274, 298, 299 |
811 |
Vitamin d3 |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
11件: 6, 13, 20, 46, 49, 53, 60, 65, 96, 97, 299 |
812 |
Vitamin d3 3000 ui daily |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 96 |
813 |
Vitamin d3 4000 ui daily |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 96 |
814 |
Vitamin d3 800 ui/day then 800 ui/day |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 96 |
815 |
Vitamin d3: 3000 or 4000 ui/day then 2,000 ui/day |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 96 |
816 |
Vitamin e |
Vitamin e |
D02331 |
- |
- |
11件: 2, 6, 13, 20, 46, 90, 96, 97, 206, 299, 317 |
817 |
Vitamin e 800iu |
Vitamin e |
D02331 |
- |
- |
2件: 96, 97 |
818 |
Vitamin k |
Phylloquinone |
D00148 |
- |
- |
3件: 13, 46, 96 |
819 |
Vitamin k 10 mg |
Phylloquinone |
D00148 |
- |
- |
1件: 96 |
820 |
Vitamin k1 |
Phylloquinone |
D00148 |
- |
- |
1件: 96 |
821 |
Vorinostat |
Vorinostat |
D06320 |
11件: HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 |
15件: Alcoholism, Amphetamine addiction, Apelin signaling pathway, Cell cycle, Chronic myeloid leukemia, Epstein-Barr virus infection, Human papillomavirus infection, Huntington disease, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Notch signaling pathway, Pathways in cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Viral carcinogenesis |
2件: 19, 96 |
822 |
Vsl#3 |
- |
- |
- |
- |
3件: 96, 97, 291 |
823 |
Vsl#3 (original de simone formulation) |
- |
- |
- |
- |
2件: 96, 97 |
824 |
Vsl#3® |
- |
- |
- |
- |
2件: 96, 97 |
825 |
Warfarin |
Warfarin |
D00564, D01280, D08682 |
2件: NQO1, VKORC1 |
5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
10件: 6, 8, 13, 19, 46, 49, 66, 85, 88, 96 |
826 |
Warfarin 10 mg |
Warfarin |
D00564, D01280, D08682 |
2件: NQO1, VKORC1 |
5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
1件: 96 |
827 |
Wellbutrin (bupropion) |
Bupropion |
D00817, D07591, D07938 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
1件: 96 |
828 |
Whey protein |
- |
- |
- |
- |
2件: 6, 96 |
829 |
Z-206 |
- |
- |
- |
- |
2件: 96, 97 |
830 |
Zoledronic acid |
Zoledronic acid |
D01968, D06378, D06379, D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
9件: 6, 13, 46, 93, 95, 96, 274, 299, 333 |
831 |
Zp1848 |
- |
- |
- |
- |
1件: 96 |
832 |
Ácido gadobénico |
- |
- |
- |
- |
1件: 96 |